To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Delta 9-THC has better analgesic effect compared to placebo for neuropathic pain over 8 hours

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
October 2018

Delta 9-THC has better analgesic effect compared to placebo for neuropathic pain over 8 hours

Vol: 7| Issue: 10| Number:1| ISSN#: 2564-2537
Study Type:Randomized Trial
OE Level Evidence:1
Journal Level of Evidence:N/A

An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease

J Pain. 2016 Sep;17(9):982-1000. doi: 10.1016/j.jpain.2016.05.010

Contributing Authors:
H Zhao B Wilsey R Deutsch TD Marcotte H Prasad A Phan

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

42 patients with neuropathic pain related to spinal cord injury and disease took a placebo, 2.9%, and 6.7% delta 9-THC in a randomized order. The primary outcome was pain intensity, and patients were also assessed for allodynia, heat-pain threshold, response to painful stimuli, subjective psychoactive effects, spasticity, and vital signs. Patients also completed neuropsychological tests after taki...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue